Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nobuaki Ochi

Showing results (11-20 of 101) with videos related to

Pageof 11
Sort By:
Plos One|November 17, 2009
Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing resultsIsao Oze, Katsuyuki Hotta, Katsuyuki Kiura, et al.
Drug Development Research|September 8, 2025
Lazertinib: A Cardio-Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double-Mutant Tyrosine Kinase Resistant Non-Small Cell Lung CancerChandrakant S Gawli, Narendra R Nagpure, Bhatu R Patil, et al.
Lung Cancer (Amsterdam, Netherlands)|July 28, 2012
Disappearance of an activated EGFR mutation after treatment with EGFR tyrosine kinase inhibitorsYoshihiro Honda, Nagio Takigawa, Soichiro Fushimi, et al.
Japanese Journal of Clinical Oncology|July 28, 2025
Utility of ultrasound-guided transbronchial needle biopsy using an acquire needle in the diagnosis of chest and mediastinal diseasesDaisuke Minami, Nagio Takigawa, Tatsuyuki Kawahara, et al.
Lung Cancer (Amsterdam, Netherlands)|June 21, 2011
Detection of the EGFR mutation in exhaled breath condensate from a heavy smoker with squamous cell carcinoma of the lungDan Zhang, Nagio Takigawa, Nobuaki Ochi, et al.
Experimental Cell Research|May 16, 2016
Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung CancerNobuaki Ochi, Hideko Isozaki, Masami Takeyama, et al.
Oncotargets and Therapy|March 16, 2013
Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentationHiromichi Yamane, Nobuaki Ochi, Masayuki Yasugi, et al.
Diagnostic Pathology|June 3, 2014
Histological comparison between preoperative and surgical specimens of non-small cell lung cancer for distinguishing between "squamous" and "non-squamous" cell carcinomaTomoko Yamagishi, Katsuhiko Shimizu, Nobuaki Ochi, et al.
Therapeutics and Clinical Risk Management|September 4, 2018
Drug-induced interstitial lung disease in the treatment of malignant lymphoma as a potential diagnostic marker: a comparison of serum Krebs von Lungen-6 and thymus and activation-regulated chemokine/CC chemokine ligand 17Hiromichi Yamane, Nobuaki Ochi, Yasunari Nagasaki, et al.
Anticancer Research|March 9, 2012
Cytotoxicity of activated natural killer cells and expression of adhesion molecules in small-cell lung cancerTadashi Tsuchida, Hiromichi Yamane, Nobuaki Ochi, et al.
Pageof 11

Showing results (11-20 of 101) with videos related to

Sort By:
Pageof 11
Plos One|November 17, 2009
Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing resultsIsao Oze, Katsuyuki Hotta, Katsuyuki Kiura, et al.
Drug Development Research|September 8, 2025
Lazertinib: A Cardio-Safer Alternative to Osimertinib for Epidermal Growth Factor Receptor L858R/T790M Double-Mutant Tyrosine Kinase Resistant Non-Small Cell Lung CancerChandrakant S Gawli, Narendra R Nagpure, Bhatu R Patil, et al.
Lung Cancer (Amsterdam, Netherlands)|July 28, 2012
Disappearance of an activated EGFR mutation after treatment with EGFR tyrosine kinase inhibitorsYoshihiro Honda, Nagio Takigawa, Soichiro Fushimi, et al.
Japanese Journal of Clinical Oncology|July 28, 2025
Utility of ultrasound-guided transbronchial needle biopsy using an acquire needle in the diagnosis of chest and mediastinal diseasesDaisuke Minami, Nagio Takigawa, Tatsuyuki Kawahara, et al.
Lung Cancer (Amsterdam, Netherlands)|June 21, 2011
Detection of the EGFR mutation in exhaled breath condensate from a heavy smoker with squamous cell carcinoma of the lungDan Zhang, Nagio Takigawa, Nobuaki Ochi, et al.
Experimental Cell Research|May 16, 2016
Synergistic effect of pacritinib with erlotinib on JAK2-mediated resistance in epidermal gowth factor receptor mutation-positive non-small cell lung CancerNobuaki Ochi, Hideko Isozaki, Masami Takeyama, et al.
Oncotargets and Therapy|March 16, 2013
Docetaxel for non-small-cell lung cancer harboring the activated EGFR mutation with T790M at initial presentationHiromichi Yamane, Nobuaki Ochi, Masayuki Yasugi, et al.
Diagnostic Pathology|June 3, 2014
Histological comparison between preoperative and surgical specimens of non-small cell lung cancer for distinguishing between "squamous" and "non-squamous" cell carcinomaTomoko Yamagishi, Katsuhiko Shimizu, Nobuaki Ochi, et al.
Therapeutics and Clinical Risk Management|September 4, 2018
Drug-induced interstitial lung disease in the treatment of malignant lymphoma as a potential diagnostic marker: a comparison of serum Krebs von Lungen-6 and thymus and activation-regulated chemokine/CC chemokine ligand 17Hiromichi Yamane, Nobuaki Ochi, Yasunari Nagasaki, et al.
Anticancer Research|March 9, 2012
Cytotoxicity of activated natural killer cells and expression of adhesion molecules in small-cell lung cancerTadashi Tsuchida, Hiromichi Yamane, Nobuaki Ochi, et al.
Pageof 11